Integra Lifesciences Holdings (IART) Depreciation & Amortization (CF) (2009 - 2026)

Integra Lifesciences Holdings has reported Depreciation & Amortization (CF) for 18 years, with the latest figure at $38.1 million in Q2 2026.

• Quarterly Depreciation & Amortization (CF) rose 1.18% year-over-year to $38.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $153.5 million (up 3.43% YoY) and the FY2025 annual result came in at $151.8 million, up 7.76% from the prior year.
• Depreciation & Amortization (CF) fell to $38.1 million in Q2 2026 per IART's latest filing, from $38.4 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $38.5 million in Q3 2025 and troughed at $29.5 million in Q3 2022.
• A 5-year average of $34.0 million and a median of $33.6 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) fell 4.07% in 2022, then advanced 21.66% in 2025.
• Over 5 years, Depreciation & Amortization (CF) stood at $29.5 million in 2022, then increased by 5.05% to $31.0 million in 2023, then rose by 21.31% to $37.6 million in 2024, then gained by 2.24% to $38.4 million in 2025, then decreased by 0.77% to $38.1 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $38.1 million, $38.4 million, and $38.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.